Thermo Fisher beats Q3 estimates and raises 2026 guidance; $60M tariff-refund boost is largely one-time
What happened
Thermo Fisher Scientific reported Q3 adjusted EPS of $6.68, beating the $6.40 consensus by $0.28, on revenue of $12.14 billion (+9% YoY, 6% organic) versus $11.95 billion expected. Adjusted operating margin expanded 120 basis points to 24.5%, with growth led by Pharma Services, clinical research, electron microscopy and improving biotech demand. The company raised its full-year 2026 outlook: revenue $47.7-48.2 billion, organic growth 4%, adjusted EPS $25.13-25.43, and free cash flow $7.0-7.5 billion. However, the quarter benefited from approximately $60 million of net tariff-refund recovery contributing $0.15 to adjusted EPS — a largely one-time benefit that the company partly reinvested in AI deployment, Pharma Services capacity and employee investments. Fourth-quarter organic growth guidance holds at 4% after some Pharma Services activity shifted into Q3. The market reaction was muted: commentary notes the stock 'shrugged off' the beat given the rich multiple and the non-recurring lift.
Why it matters & what’s next are part of Pro, along with the audio summary.
Start your free 14-day trialWho’s affected
- TMO — beat and raise met with a muted market reaction at ~26x forward earnings
- Life-science tools peers (DHR, A, MTD) — confirms improving biotech/pharma spending and bioproduction demand
- Biotech sector — improving biotech funding and confidence read-through
Sources